NO20025302L - Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler - Google Patents

Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler

Info

Publication number
NO20025302L
NO20025302L NO20025302A NO20025302A NO20025302L NO 20025302 L NO20025302 L NO 20025302L NO 20025302 A NO20025302 A NO 20025302A NO 20025302 A NO20025302 A NO 20025302A NO 20025302 L NO20025302 L NO 20025302L
Authority
NO
Norway
Prior art keywords
monoclonal anti
aromatase inhibitors
antitumor agents
her2 antibodies
her2
Prior art date
Application number
NO20025302A
Other languages
English (en)
Other versions
NO20025302D0 (no
Inventor
Giorgio Massimini
Gabrielle Piscitelli
Dinesh Purandare
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20025302D0 publication Critical patent/NO20025302D0/no
Publication of NO20025302L publication Critical patent/NO20025302L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20025302A 2000-05-15 2002-11-05 Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler NO20025302L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Publications (2)

Publication Number Publication Date
NO20025302D0 NO20025302D0 (no) 2002-11-05
NO20025302L true NO20025302L (no) 2002-11-05

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025302A NO20025302L (no) 2000-05-15 2002-11-05 Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler

Country Status (20)

Country Link
EP (1) EP1282440A1 (no)
JP (1) JP2003533490A (no)
KR (1) KR20030014223A (no)
CN (1) CN1429118A (no)
AU (1) AU784617B2 (no)
BR (1) BR0110732A (no)
CA (1) CA2409652A1 (no)
CZ (1) CZ20023748A3 (no)
EA (1) EA005931B1 (no)
EE (1) EE200200622A (no)
HK (1) HK1054200A1 (no)
HU (1) HUP0301877A2 (no)
IL (1) IL152389A0 (no)
MX (1) MXPA02011194A (no)
NO (1) NO20025302L (no)
NZ (1) NZ523004A (no)
PL (1) PL360153A1 (no)
SK (1) SK16022002A3 (no)
WO (1) WO2001087334A1 (no)
ZA (1) ZA200209815B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
DK1282443T3 (da) 2000-05-19 2010-01-04 Genentech Inc Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi
MXPA03006607A (es) * 2001-01-26 2003-09-22 Upjohn Co Metodo combinado para tratar trastornos dependientes de hormonas.
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
JP4660094B2 (ja) 2002-03-26 2011-03-30 ゼンサン （シャンハイ） サイ−テク． リミテッド 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
CN1678348A (zh) * 2002-07-01 2005-10-05 萨文特医药公司 用于治疗性治疗的组合物和方法
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP2322217A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
CN103251946A (zh) 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2536748B1 (en) 2010-02-18 2014-08-20 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
RU2014126098A (ru) 2011-11-30 2016-01-27 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CN104813168B (zh) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 需要pd‑l1抑制剂综合疗法的患者的鉴定
JP2017531685A (ja) 2014-10-22 2017-10-26 ハバフ セラピューティクス ピーティーワイ エルティーディー マンモグラフィ乳房密度及び／又は乳癌リスクを低下させる方法
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
US11524014B2 (en) 2019-06-03 2022-12-13 Havah Therapeutics Pty Ltd. Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
MXPA02011194A (es) 2003-03-10
BR0110732A (pt) 2003-02-04
SK16022002A3 (sk) 2003-04-01
CA2409652A1 (en) 2001-11-22
NO20025302D0 (no) 2002-11-05
CZ20023748A3 (cs) 2003-04-16
HUP0301877A2 (hu) 2003-09-29
KR20030014223A (ko) 2003-02-15
EE200200622A (et) 2004-06-15
JP2003533490A (ja) 2003-11-11
ZA200209815B (en) 2003-12-03
AU784617B2 (en) 2006-05-18
EA005931B1 (ru) 2005-08-25
HK1054200A1 (zh) 2003-11-21
EP1282440A1 (en) 2003-02-12
PL360153A1 (en) 2004-09-06
CN1429118A (zh) 2003-07-09
AU5630901A (en) 2001-11-26
WO2001087334A1 (en) 2001-11-22
EA200201213A1 (ru) 2003-04-24
NZ523004A (en) 2004-09-24
IL152389A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
NO20025302D0 (no) Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
NO20031642L (no) Humaniserte anti-LT-ß-R-antistoff
DK1501856T3 (da) Anti-HER2 antistofvarianter
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO20054351D0 (no) Monoklonalt antistoff og hybridom som produserer dette
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20032549L (no) Humaniserte antistoffer som gjenkjenner beta-amyloid-peptid
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
NO20044347L (no) Anti-alfavbeta6-antistoff
IS8115A (is) Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra
NO20035366L (no) Benzoylsulfonamider og sulfonylbenzamidiner for anvendelse som antitumormidler
EP1572077A4 (en) USES OF MONOCLONAL 8H9 ANTIBODIES
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
ATE480564T1 (de) Monoklonaler anti-mensch-tenascin-antikörper
DE60223191D1 (de) Ausgeber für Arzneimittel
AU2003220079A8 (en) Uses of monoclonal antibody 8h9
EE200300569A (et) CD44v6-spetsiifilised antikehad
BR0207810A (pt) inibidores de deformilase de peptìdeo
DE60105696D1 (de) Eisenhaltige Proteinzusammensetzung
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
ITPD20000192A0 (it) Anticorpi policlonali
GB0121727D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application